VYD2311-SD

Phase 3Small molecule

IInvivyd, Inc.

VYD2311-SD is one of 21 small molecule programs targeting COVID-19. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

COVID-19 Vaccine

Moderna

Preclinical

27 2

VYD2311-SD

IInvivyd, Inc.

Phase 3

1 3

Singulair

AstraZeneca

Preclinical

1 4

Activella

Eli Lilly

Preclinical

—5

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 6

Nitrostat

VViatris Specialty LLC

Preclinical

1 7

SARS-COV-2 VACCINE

Moderna

Preclinical

2 8

Achromycin V

WWyeth-Lederle Vaccines

Statins

1 10

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-191 trial

Study of VYD2311 for the Prevention of COVID-19

Active, not recruiting·IInvivyd, Inc.·Phase 3·NCT07298434·1,770 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VYD2311-SD. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VYD2311-SD compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VYD2311-SD. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Invivyd, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IInvivyd, Inc.

VYD2311-SD

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COVID-191 trial

References

Drug Info

Quick Facts

Related News